Yang Z - Search Results

1

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Ballard P, et al. Among authors: yang jc, yang z. Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. doi: 10.1158/1078-0432.CCR-16-0399. Epub 2016 Jul 19. Clin Cancer Res. 2016. PMID: 27435396

2

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

Ye X, Zhu ZZ, Zhong L, Lu Y, Sun Y, Yin X, Yang Z, Zhu G, Ji Q. Ye X, et al. Among authors: yang z. J Thorac Oncol. 2013 Sep;8(9):1118-20. doi: 10.1097/JTO.0b013e31829f691f. J Thorac Oncol. 2013. PMID: 23945382 Free article. No abstract available.

3

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

Zeng Q, Wang J, Cheng Z, Chen K, Johnström P, Varnäs K, Li DY, Yang ZF, Zhang X. Zeng Q, et al. Among authors: yang zf. J Med Chem. 2015 Oct 22;58(20):8200-15. doi: 10.1021/acs.jmedchem.5b01073. Epub 2015 Oct 9. J Med Chem. 2015. PMID: 26313252

4

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.

Zhao J, Ye X, Xu Y, Chen M, Zhong W, Sun Y, Yang Z, Zhu G, Gu Y, Wang M. Zhao J, et al. Among authors: yang z. Cancer Chemother Pharmacol. 2016 Dec;78(6):1305-1310. doi: 10.1007/s00280-016-3155-y. Epub 2016 Oct 21. Cancer Chemother Pharmacol. 2016. PMID: 27770237

5

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.

Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW, Ahn MJ, Yang JC, Zhang X. Yang Z, et al. Among authors: yang jc. Sci Transl Med. 2016 Dec 7;8(368):368ra172. doi: 10.1126/scitranslmed.aag0976. Sci Transl Med. 2016. PMID: 27928026

6

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.

Li A, Yang JJ, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong WZ, Chuai S, Zhang Q, Xie Z, Gao H, Chen H, Wang Z, Wang Z, Yang XN, Wang BC, Gan B, Chen ZH, Jiang BY, Wu SP, Liu SY, Xu CR, Wu YL. Li A, et al. Among authors: yang xn, yang jj, yang z. Clin Cancer Res. 2017 Aug 15;23(16):4929-4937. doi: 10.1158/1078-0432.CCR-16-3273. Epub 2017 Apr 10. Clin Cancer Res. 2017. PMID: 28396313

7

EGFR G796D mutation mediates resistance to osimertinib.

Zheng D, Hu M, Bai Y, Zhu X, Lu X, Wu C, Wang J, Liu L, Wang Z, Ni J, Yang Z, Xu J. Zheng D, et al. Among authors: yang z. Oncotarget. 2017 Jul 25;8(30):49671-49679. doi: 10.18632/oncotarget.17913. Oncotarget. 2017. PMID: 28572531 Free PMC article.

8

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. Ahn MJ, et al. Among authors: yang jc, yang z. Lancet Respir Med. 2017 Nov;5(11):891-902. doi: 10.1016/S2213-2600(17)30378-8. Epub 2017 Oct 19. Lancet Respir Med. 2017. PMID: 29056570 Clinical Trial.

9

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

Kang J, Chen HJ, Wang Z, Liu J, Li B, Zhang T, Yang Z, Wu YL, Yang JJ. Kang J, et al. Among authors: yang jj, yang z. J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8. J Thorac Oncol. 2018. PMID: 29128427 Free article. No abstract available.

10

Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.

Li X, Wang Y, Wang J, Zhang T, Zheng L, Yang Z, Xing L, Yu J. Li X, et al. Among authors: yang z. Int J Cancer. 2018 Jul 1;143(1):212-224. doi: 10.1002/ijc.31303. Epub 2018 Mar 1. Int J Cancer. 2018. PMID: 29430654 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45,309 results

Search Page